Genetic Variants Linked to Bleeding Risk in Warfarin Patients

the MPR take:

The first study to find an association between a gene variant and clinically significant decreased risk of major bleeding in patients taking warfarin has been published in the journal Clinical Pharmacology & Therapeutics. In evaluating 205 patients in a community setting on warfarin therapy, those with the common CYP4F2*3 variant had a 38% lower major bleeding risk compared to patients without this variant. This suggests that testing for CYP4F2*3 status could be important for personalizing treatment, particularly since an increased dose is needed for patients with the variant to achieve therapeutic INR levels.

Genetic Variants Linked to Bleeding Risk in Warfarin Patients
Genetic Variants Linked to Bleeding Risk in Warfarin Patients
The influence of warfarin pharmacogenomics on major bleeding risk has been little studied in long-term users and non–specialist care settings. We conducted a case–control study to evaluate associations between CYP2C9*2/*3, VKORC1(1173), and CYP4F2*3 variants and major bleeding among patients treated with warfarin in a community setting.

READ FULL ARTICLE From Nature

Loading links....